Fig. 5.

SeNP treatment enhance the cell apoptosis of the prostate cancer cells through miR-16 upregulation. a Sequence alignment of miR-16 and its target sites in 3′ untranslated regions of BCL-2 and cyclin D1. BCL-2 and cyclin D1 mutant site was shown in red. b HEK293 cells were transiently co-transfected with luciferase report vectors, and either miR-16 mimics or scrambled miR-control. Luciferase activities were normalized to the activity of Renilla luciferase. c LNCaP and d LNCaP-A were transient transfected with miR-16 inhibitor, together with SeNP treatment, and the protein expressions of BCL-2 and cyclin D1 were determined. e LNCaP and f LNCaP-A were transient transfected with miR-16 inhibitor, together with SeNP treatment, and the inhibition percentages expressed by the SeNPs were determined. The %inhibition values were calculated by subtracting the growth percentages from 100. SeNP dose: 50 μg